^
Association details:
| Biomarker: | KIF5B-ALK fusion + ALK L1196M |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report
Published date:
03/22/2021
Excerpt:
...a 70-year-old nonsmoking Chinese man, with rare ALK rearrangement form of, namely, a kinesin family member 5B (KIF5B)-ALK (K20:A20) fusion which was identified in tissue by capture-based NGS....Additionally, an ALK L1196M mutation was detected when the disease progressed after 11 months and was indicated to be sensitive to ceritinib....the patient reported in our case achieved a long PFS of 9 months with the administration of ceritinib with ongoing follow-up.
DOI:
10.21037/apm-20-2081
